Iris Tavor
General Counsel chez ENLIVEX THERAPEUTICS LTD.
Profil
Iris Tavor is currently a Senior Director of Regulatory and Quality Affairs at Enlivex Therapeutics Ltd.
She previously worked as the Head of Quality and Regulatory Affairs at Pluristem Ltd.
Postes actifs de Iris Tavor
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | General Counsel | - |
Anciens postes connus de Iris Tavor
| Sociétés | Poste | Fin |
|---|---|---|
Pluristem Ltd.
 Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | General Counsel | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Pluristem Ltd.
Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The private company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
